Palvella Therapeutics (PVLA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Corporate strategy and vision

• Focused on serving patients with rare skin diseases and vascular malformations lacking FDA-approved therapies.

• Aims to be first to market with targeted therapies and commercialize independently.

• Sees rare skin diseases as a high unmet need with low competitive intensity, targeting leadership in this space.

• Built a late-stage pipeline and the QTORIN platform for novel topical therapies.

• Strong capital base with $260 million in cash to support key milestones.

QTORIN platform and technology

• QTORIN enables reproducible generation of novel topical candidates for rare skin diseases.

• Tested over 15 molecules, achieving high concentrations and targeted dermal delivery.

• Technology retains drugs in the skin, minimizing systemic absorption and toxicity.

• Each candidate brings new formulation and method-of-use IP, aiming for long-duration protection.

• Internal product development engine reduces reliance on external licensing.

Lead program: QTORIN rapamycin for microcystic lymphatic malformations (mLM)

• Positive phase III data announced, meeting all primary and secondary endpoints.

• 95% of patients improved; 86% achieved high improvement scores; low adverse events.

• 100% of younger patients (6-11) much or very much improved and remained on therapy in extension.

• NDA submission planned for the second half of the year, following supportive FDA interactions.

• Market estimated at over 30,000 U.S. patients, with a $3–6 billion addressable opportunity.